Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Overview
- Response deadline
- 12:00 PM CDT
- Posted
- February 10, 2026
- Notice type
- Solicitation
- Set-aside
- No Set aside used
- Agency
- Department of WarDEFENSE HEALTH AGENCY (DHA)
Notice details
- Office
- DEFENSE HEALTH AGENCY (DHA)
- Place of performance
- San Antonio, Texas, 78230
- Last updated
- Nov 4, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- HT9402-26-Q-9201
- Notice ID
- fe66d512d41448bb81e795cdc32fc134
Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P& T COMMITTEE MEETING: The following MAY 2026 drug classes/subclasses will be reviewed:
a. Antihemophilic Agents - Non-Factor Agents
- ALHEMO PEN
- HEMLIBRA
- HYMPAVZI PEN
- QFITLIA
b. Leukemia and Lymphoma - BCR-ABL-TKI
- BOSULIF
- DANZITEN
- ICLUSIG
- IMKELDI
- PHYRAGO
- SCEMBLIX
- SPRYCEL
- TASIGNA
- NILOTINIB TARTRATE
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9201. Pre-quotation teleconference is on February 11, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (5)
- Download
RFQ HT9402-26-Q-9201 CR.pdf
1.6 MBAdded in Solicitation version 1Posted - Download
A-3 NDC Price List Antihemophilic Ag - Non-Fac Ag.xlsx
47 KBAdded in Solicitation version 1Posted - Download
A-3 NDC Price List Leukemia and Lymphoma - BCR-ABL-TKI.xlsx
47 KBAdded in Solicitation version 1Posted - Download
May 2026 PT Meeting Reporting.xlsx
136 KBAdded in Solicitation version 1Posted - Download
NDC Price List FAQ Class Review.pdf
227 KBAdded in Solicitation version 1Posted
Links (1)
- https://health.mil/PandThealth.milPosted
Lifecycle
- 1Version 1SolicitationArchived
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
- 3Version 3SolicitationArchivedCurrent
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
HT9402-26-Q-9201
Archive Date
Oct 2, 2026
Office Address
JBSA FT SAM HOUSTON, TX, 78234